OTC · Drug Manufacturers - Specialty & Generic

Revive Therapeutics Ltd. (RVVTF) Stock

$0.02 -2.56% OTC: RVVTF Healthcare

Revive Therapeutics Ltd., a life sciences firm founded in 2012 and headquartered in Toronto, Canada, is focused on discovering and advancing treatments for uncommon diseases and infectious illnesses. The company maintains a pharmaceutical pipeline centered on cannabinoids, specifically targeting rare inflammatory conditions.

Valuation

MetricValue
Price$0.02
Market Cap$8.28M
P/E Ratio-1.09
P/B Ratio-2.71
P/S Ratio0.00
EPS (TTM)$-0.03
52-Week High$0.06
52-Week Low$0.00
Dividend Yield—

Financials & Margins

MetricValue
ROE288.66%
ROA—
ROCE33.44%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.02
Current Ratio0.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-18.0M$-6.0M$-3.0M$-2.0M
Net Profit$-20.0M$-18.0M$-6.0M$-6.0M$-11.0M
EPS$-0.08$-0.06$-0.02$-0.01$-0.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$30.0M$17.0M$14.0M$11.0M$0
Total Liabilities$1.0M$4.0M$4.0M$3.0M$4.0M
Cash$17.0M$4.0M$2.0M$1.0M$0
Borrowings$0$0$0$0$0

Latest News

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement ACCESS Newswire · Jul 15, 2026 Revive Therapeutics Announces Proposed Private Placement ACCESS Newswire · Jun 26, 2026 Canadian Investment Regulatory Organization Trading Halt - RVV CNW Group · Jun 8, 2026 Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures ACCESS Newswire · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-13.0M$-6.0M$-3.0M$-1.0M
Investing Cash Flow$-6.0M$0$0$0$0
Financing Cash Flow$-2.0M$0$0$0$0
Net Cash Flow$15.0M$-13.0M$-2.0M$-1.0M$-1.0M
Free Cash Flow$-11.0M$-13.0M$-6.0M$-3.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-12.08%
Quick Ratio0.04
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.51%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Curio Wealth, LLC 1,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BETR.CNBetterLife Pharma Inc. $0.26 -3.70% -30.00 $157.59M 0.00%
BNXT.CNBioNxt Solutions Inc. $0.33 -13.16% -4.86 $47.63M 0.00%
CYBN.NE — — — — 0.00%
DRUG.CNBright Minds Biosciences Inc. $77.10 +9.22% -10.98 $880.04M 0.00%
LOBE.CNLobe Sciences Ltd. $0.06 +0.00% -2.25 $24.65M 0.00%

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd., a life sciences firm founded in 2012 and headquartered in Toronto, Canada, is focused on discovering and advancing treatments for uncommon diseases and infectious illnesses. The company maintains a pharmaceutical pipeline centered on cannabinoids, specifically targeting rare inflammatory conditions. Key developments in its therapeutic portfolio include: Bucillamine: Currently in Phase 3 clinical trials, it is being investigated for combating infectious diseases such as influenza and COVID-19. Psilocybin: This compound is in Phase 1 clinical studies for its potential in treating methamphetamine use disorder. Psilocin: The company is exploring its application for a range of mental health challenges, including depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. Cannabidiol (CBD): This is under investigation for its use in autoimmune hepatitis and for reducing ischemia and reperfusion injury that can occur after organ transplantation. Revive Therapeutics Ltd. also engages in several strategic research partnerships. These collaborations include an alliance with PharmaTher Inc. to develop psilocybin for cancer treatment and to identify new applications for other psychedelic compounds; a project with North Carolina State University to create a biosynthetic version of psilocybin through an enzymatic platform; a joint effort with the University of California, San Francisco, to assess Bucillamine's effectiveness against severe COVID-19; clinical research into psychedelics with the University of Health Sciences Antigua; and another collaboration with PharmaTher for the advancement of a psilocybin microneedle patch.

Revive Therapeutics Ltd. is headquartered in CA.

Revive Therapeutics Ltd. (RVVTF) stock trades at $0.02 with a market capitalization of $8.28M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.09, reflecting a net loss over the last twelve months, a negative price-to-book of -2.71, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.06, and currently trades 66.7% below its 52-week high.

On profitability, Revive Therapeutics Ltd. generates a return on equity (ROE) of 288.66% (not meaningful, as shareholders' equity is negative), return on capital employed of 33.44%.

Official website: www.revivethera.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.